Ustekinumab biosimilar (CSPC Pharma)

乌司奴单抗生物类似药（石药集团）

Report date: 2026/05/27 15:15:15

Base Information

Drug NameUstekinumab biosimilar (CSPC Pharma)
Drug Alias Name恩益克SYSA-1902
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionInterleukin-12 inhibitorsInterleukin-23 inhibitors
TargetsInterleukin-12Interleukin-23
Therapy Area/IndicationsPlaque psoriasis
Global Approved IndicationsPlaque psoriasis
Approved Indications in ChinaPlaque psoriasis
Original Approved Country/TerritoryMainland China
Original Approved Date2026/05/19
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJushi Biopharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesJushi Biopharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsPlaque psoriasis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG